Consistent safety and tolerability in adults with bipolar I and bipolar II depression across clinical trials¹

Most common adverse reactions in 6-week bipolar depression trials^1*

CAPLYTA demonstrated safety in 2664 adult patients with schizophrenia and bipolar depression¹

^*>5% of patients exposed to CAPLYTA and greater than twice the rate of placebo.¹

^†Dizziness, dizziness postural.¹

There was no single adverse reaction leading to discontinuation that occurred at a rate of >2% in patients treated with CAPLYTA¹

Antipsychotic drugs have been reported to cause:

Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.

Helpful tools & resources

Also in this section:

Reference: 1. CAPLYTA prescribing information.